Palatin Technologies (PTN) Current Leases (2011 - 2026)
Palatin Technologies' (PTN) quarterly Current Leases came in at $189205.0 in Q1 2026, down 2.96% on a YoY basis from $194972.0 in Q1 2025, and down 13.89% quarter-over-quarter from $219727.0 in Q4 2025.
Analysis
Palatin Technologies (PTN) Current Leases (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Current Leases for 13 consecutive years, with $189205.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Current Leases fell 2.96% year-over-year to $189205.0; the trailing twelve-month figure through Mar 2026 stood at $189205.0 (down 2.96% YoY), and the FY2025 full-year result was $129812.0, down 65.89% from the prior year.
- Current Leases eased to $189205.0 in Q1 2026 per PTN's latest filing, from $219727.0 in the prior quarter.
- Across five years, Current Leases topped out at $380542.0 in Q2 2024 and bottomed at $129812.0 in Q2 2025.
- Historically, Current Leases has averaged $291714.5 across 5 years, with a median of $326947.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Current Leases increased 23.28% in 2024, then plunged 65.89% in 2025.
- Over 5 years, Current Leases stood at $335732.0 in 2022, then grew by 8.34% to $363718.0 in 2023, then retreated by 29.16% to $257673.0 in 2024, then slipped by 14.73% to $219727.0 in 2025, then fell by 13.89% to $189205.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $189205.0, $219727.0, and $132446.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 720.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 11.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 12.38 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 189,205.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 189,205.00 |
| Dec 31, 2025 | 219,727.00 |
| Sep 30, 2025 | 132,446.00 |
| Jun 30, 2025 | 129,812.00 |
| Mar 31, 2025 | 194,972.00 |
| Dec 31, 2024 | 257,673.00 |
| Sep 30, 2024 | 319,520.00 |
| Jun 30, 2024 | 380,542.00 |
| Mar 31, 2024 | 371,280.00 |
| Dec 31, 2023 | 363,718.00 |
| Sep 30, 2023 | 326,947.00 |
| Jun 30, 2023 | 354,052.00 |
| Mar 31, 2023 | 301,169.00 |
| Dec 31, 2022 | 335,732.00 |
| Sep 30, 2022 | 343,749.00 |
| Jun 30, 2022 | 371,124.00 |
| Mar 31, 2022 | 367,478.00 |
| Dec 31, 2021 | 360,655.00 |
| Sep 30, 2021 | 353,925.00 |
| Jun 30, 2021 | 351,853.00 |